Walker 256 tumour cells increase substance P immunoreactivity locally and modify the properties of the blood-brain barrier during extravasation and brain invasion

Clinical and Experimental Metastasis

Volumn 30, Issue 1, 2013, Pages 1-12

  Lewis, Kate M ^a   Harford Wright, Elizabeth ^a   Vink, Robert ^a   Nimmo, Alan J ^a   Ghabriel, Mounir N ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Blood brain barrier; Brain metastases; Endothelial barrier antigen; Extravasation; Neurogenic inflammation; Substance P

Indexed keywords

ALBUMIN; ANTIGEN; ENDOTHELIAL BARRIER ANTIGEN; SUBSTANCE P; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN BLOOD VESSEL; BREAST CARCINOMA; CANCER INVASION; CANCER STAGING; CONTROLLED STUDY; CULTURE MEDIUM; EXTRAVASATION; IMMUNOREACTIVITY; INOCULATION; INTERNAL CAROTID ARTERY; NONHUMAN; RAT; WALKER CARCINOMA;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CAPILLARY PERMEABILITY; CARCINOMA 256, WALKER; FEMALE; IMMUNOHISTOCHEMISTRY; MALE; MAMMARY NEOPLASMS, ANIMAL; RATS; RATS, WISTAR; SUBSTANCE P; TUMOR CELLS, CULTURED;

EID: 84872675731     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-012-9487-z     Document Type: Article

References (69)

1. WHO (2002) National Cancer Control Programmes: policies and managerial guidelines
2. Cifuentes N, Pickren JW (1979) Metastases from carcinoma of mammary gland: an autopsy study. J Surg Oncol 11(3):193-205
3. Posner JB, Chernik NL (1978) Intracranial metastases from systemic cancer. Adv Neurol 19:579-592
4. Gavrilovic IT, Posner JB (2005) Brain metastases: epidemiology and pathophysiology. J Neurooncol 75(1):5-14
5. Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, Harris GJ, Bullitt E, Van den Abbeele AD, Henson JW, Li X, Gelman R, Burstein HJ, Kasparian E, Kirsch DG, Crawford A, Hochberg F, Winer EP (2008) Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 26 (12):1993-1999. doi: 10.1200/JCO.2007.12.3588
6. Soffietti R, Ruda R, Mutani R (2002) Management of brain metastases. J Neurol 249(10):1357-1369
7. Lorger M, Felding-Habermann B (2010) Capturing changes in the brain microenvironment during initial steps of breast cancer brain metastasis. Am J Pathol 176(6):2958-2971
8. Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP (2008) Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 113(10):2638-2645
9. Pestalozzi BC, Zahrieh D, Price KN, Holmberg SB, Lindtner J, Collins J, Crivellari D, Fey MF, Murray E, Pagani O, Simoncini E, Castiglione-Gertsch M, Gelber RD, Coates AS, Goldhirsch A (2006) Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 17(6):935-944
10. Marchetti D, Denkins Y, Reiland J, Greiter-Wilke A, Galjour J, Murry B, Blust J, Roy M (2003) Brain-metastatic melanoma: a neurotrophic perspective. Pathol Oncol Res 9(3):147-158
11. Hawkins BT, Davis TP (2005) The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 57(2):173-185
12. Schackert G, Simmons RD, Buzbee TM, Hume DA, Fidler IJ (1988) Macrophage infiltration into experimental brain metastases: occurrence through an intact blood-brain barrier. J Natl Cancer Inst 80(13):1027-1034
13. Juanyin J, Tracy K, Zhang L, Munasinghe J, Shapiro E, Koretsky A, Kelly K (2009) Noninvasive imaging of the functional effects of anti-VEGF therapy on tumor cell extravasation and regional blood volume in an experimental brain metastasis model. Clin Exp Metastasis 26(5):403-414
14. Fazakas C, Wilhelm I, Nagyoszi P, Farkas AE, Hasko J, Molnar J, Bauer H, Bauer HC, Ayaydin F, Dung NT, Siklos L, Krizbai IA (2011) Transmigration of melanoma cells through the blood-brain barrier: role of endothelial tight junctions and melanoma-released serine proteases. PLoS One 6(6):e20758
15. Mendes O, Kim HT, Lungu G, Stoica G (2007) MMP2 role in breast cancer brain metastasis development and its regulation by TIMP2 and ERK1/2. Clin Exp Metastasis 24(5):341-351
16. Ribeiro-da-Silva A, Hokfelt T (2000) Neuroanatomical localisation of Substance P in the CNS and sensory neurons. Neuropeptides 34(5):256-271
17. Cioni C, Renzi D, Calabro A, Annunziata P (1998) Enhanced secretion of substance P by cytokine-stimulated rat brain endothelium cultures. J Neuroimmunol 84(1):76-85
18. Harrison S, Geppetti P (2001) Substance P. Int J Biochem Cell Biol 33(6):555-576
19. Nimmo AJ, Cernak I, Heath DL, Hu X, Bennett CJ, Vink R (2004) Neurogenic inflammation is associated with development of edema and functional deficits following traumatic brain injury in rats. Neuropeptides 38(1):40-47
20. Paemeleire K, de Hemptinne A, Leybaert L (1999) Chemically, mechanically, and hyperosmolarity-induced calcium responses of rat cortical capillary endothelial cells in culture. Exp Brain Res 126(4):473-481
21. Annunziata P, Cioni C, Santonini R, Paccagnini E (2002) Substance P antagonist blocks leakage and reduces activation of cytokine-stimulated rat brain endothelium. J Neuroimmunol 131(1-2):41-49
22. Lu TS, Avraham HK, Seng S, Tachado SD, Koziel H, Makriyannis A, Avraham S (2008) Cannabinoids inhibit HIV-1 Gp120-mediated insults in brain microvascular endothelial cells. J Immunol 181(9):6406-6416
23. Annunziata P, Cioni C, Toneatto S, Paccagnini E (1998) HIV-1 gp120 increases the permeability of rat brain endothelium cultures by a mechanism involving substance P. Aids 12(18):2377-2385
24. Lang K, Drell TLt, Lindecke A, Niggemann B, Kaltschmidt C, Zaenker KS, Entschladen F (2004) Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int J Cancer 112 (2):231-238
25. Drell TLt, Joseph J, Lang K, Niggemann B, Zaenker KS, Entschladen F (2003) Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. Breast Cancer Res Treat 80(1):63-70
26. Ruff M, Schiffmann E, Terranova V, Pert CB (1985) Neuropeptides are chemoattractants for human tumor cells and monocytes: a possible mechanism for metastasis. Clin Immunol Immunopathol 37(3):387-396
27. Palma C, Nardelli F, Manzini S, Maggi CA (1999) Substance P activates responses correlated with tumour growth in human glioma cell lines bearing tachykinin NK1 receptors. Br J Cancer 79(2):236-243
28. Huang WQ, Wang JG, Chen L, Wei HJ, Chen H (2010) SR140333 counteracts NK-1 mediated cell proliferation in human breast cancer cell line T47D. J Exp Clin Cancer Res 29(1):55-61
29. Munoz M, Rosso M, Aguilar FJ, Gonzalez-Moles MA, Redondo M, Esteban F (2008) NK-1 receptor antagonists induce apoptosis and counteract substance P-related mitogenesis in human laryngeal cancer cell line HEp-2. Invest New Drugs 26(2):111-118
30. Prasad S, Mathur A, Jaggi M, Singh AT, Mukherjee R (2007) Substance P analogs containing alpha,alpha-dialkylated amino acids with potent anticancer activity. J Pept Sci 13(8):544-548
31. Munoz M, Perez A, Rosso M, Zamarriego C, Rosso R (2004) Antitumoral action of the neurokinin-1 receptor antagonist L-733 060 on human melanoma cell lines. Melanoma Res 14(3):183-188
32. Munoz M, Rosso M, Robles-Frias MJ, Salinas-Martin MV, Rosso R, Gonzalez-Ortega A, Covenas R (2010) The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines. Lab Invest 90(8):1259-1269
33. Munoz M, Rosso M, Perez A, Covenas R, Rosso R, Zamarriego C, Piruat JI (2005) The NK1 receptor is involved in the antitumoural action of L-733,060 and in the mitogenic action of substance P on neuroblastoma and glioma cell lines. Neuropeptides 39(4):427-432
34. Mayordomo C, Garcia-Recio S, Ametller E, Fernandez-Nogueira P, Pastor-Arroyo EM, Vinyals L, Casas I, Gascon P, Almendro V (2011) Targeting of substance P induces cancer cell death and decreases the steady state of EGFR and Her2. J Cell Physiol 227(4):1358-1366
35. Lorger M, Lee H, Forsyth JS, Felding-Habermann B (2011) Comparison of in vitro and in vivo approaches to studying brain colonization by breast cancer cells. J Neurooncol 104(3):689-696
36. Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates, 4th edn. Academic Press, San Diego
37. Helps SC, Thornton E, Kleinig TJ, Manavis J, Vink R (2012) Automatic nonsubjective estimation of antigen content visualized by immunohistochemistry using color deconvolution. Appl Immunohistochem Mol Morphol 20(1):82-90
38. Harford-Wright E, Thornton E, Vink R (2010) Angiotensin-converting enzyme (ACE) inhibitors exacerbate histological damage and motor deficits after experimental traumatic brain injury. Neurosci Lett 481(1):26-29
39. Kienast Y, von Baumgarten L, Fuhrmann M, Klinkert WE, Goldbrunner R, Herms J, Winkler F (2010) Real-time imaging reveals the single steps of brain metastasis formation. Nat Med 16(1):116-122
40. Ballinger WE Jr, Schimpff RD (1979) An experimental model for cerebral metastasis: preliminary light and ultrastructural studies. J Neuropathol Exp Neurol 38(1):19-34
41. Paku S, Dome B, Toth R, Timar J (2000) Organ-specificity of the extravasation process: an ultrastructural study. Clin Exp Metastasis 18(6):481-492
42. Carbonell WS, Ansorge O, Sibson N, Muschel R (2009) The vascular basement membrane as "soil" in brain metastasis. PLoS One 4(6):e5857
43. Heyn C, Ronald JA, Ramadan SS, Snir JA, Barry AM, MacKenzie LT, Mikulis DJ, Palmieri D, Bronder JL, Steeg PS, Yoneda T, MacDonald IC, Chambers AF, Rutt BK, Foster PJ (2006) In vivo MRI of cancer cell fate at the single-cell level in a mouse model of breast cancer metastasis to the brain. Magn Reson Med 56(5):1001-1010
44. Schackert G, Price JE, Zhang RD, Bucana CD, Itoh K, Fidler IJ (1990) Regional growth of different human melanomas as metastases in the brain of nude mice. Am J Pathol 136(1):95-102
45. Hasegawa H, Ushio Y, Hayakawa T, Yamada K, Mogami H (1983) Changes of the blood-brain barrier in experimental metastatic brain tumors. J Neurosurg 59(2):304-310
46. Turner RJ, Helps SC, Thornton E, Vink R (2011) A substance P antagonist improves outcome when administered 4 h after onset of ischaemic stroke. Brain Res 1393:84-90
47. Donkin JJ, Cernak I, Blumbergs PC, Vink R (2011) A substance p antagonist reduces axonal injury and improves neurologic outcome when administered up to 12 hours after traumatic brain injury. J Neurotrauma 28(2):217-224
48. Luo W, Sharif TR, Sharif M (1996) Substance P-induced mitogenesis in human astrocytoma cells correlates with activation of the mitogen-activated protein kinase signaling pathway. Cancer Res 56(21):4983-4991
49. Friess H, Zhu Z, Liard V, Shi X, Shrikhande SV, Wang L, Lieb K, Korc M, Palma C, Zimmermann A, Reubi JC, Buchler MW (2003) Neurokinin-1 receptor expression and its potential effects on tumor growth in human pancreatic cancer. Lab Invest 83(5):731-742
50. Munoz M, Rosso M, Perez A, Covenas R, Rosso R, Zamarriego C, Soult JA, Montero I (2005) Antitumoral action of the neurokinin-1-receptor antagonist L-733,060 and mitogenic action of substance P on human retinoblastoma cell lines. Invest Ophthalmol Vis Sci 46(7):2567-2570
51. Munoz M, Rosso M, Covenas R, Montero I, Gonzalez-Moles MA, Robles MJ (2007) Neurokinin-1 receptors located in human retinoblastoma cell lines: antitumor action of its antagonist, L-732,138. Invest Ophthalmol Vis Sci 48(6):2775-2781
52. Rosso M, Robles-Frias MJ, Covenas R, Salinas-Martin MV, Munoz M (2008) The NK-1 receptor is expressed in human primary gastric and colon adenocarcinomas and is involved in the antitumor action of L-733,060 and the mitogenic action of substance P on human gastrointestinal cancer cell lines. Tumour Biol 29(4):245-254
53. Ziche M, Morbidelli L, Pacini M, Geppetti P, Alessandri G, Maggi CA (1990) Substance P stimulates neovascularization in vivo and proliferation of cultured endothelial cells. Microvasc Res 40(2):264-278
54. Wang Q, Muffley LA, Hall K, Chase M, Gibran NS (2009) Elevated glucose and fatty acid levels impair substance P-induced dermal microvascular endothelial cell migration and proliferation in an agarose gel model system. Shock 32(5):491-497
55. Munoz M, Covenas R (2011) NK-1 receptor antagonists: a new paradigm in pharmacological therapy. Curr Med Chem 18(12):1820-1831
56. Ghabriel MN, Zhu C, Hermanis G, Allt G (2000) Immunological targeting of the endothelial barrier antigen (EBA) in vivo leads to opening of the blood-brain barrier. Brain Res 878(1-2):127-135
57. Ghabriel MN, Zhu C, Leigh C (2002) Electron microscope study of blood-brain barrier opening induced by immunological targeting of the endothelial barrier antigen. Brain Res 934(2):140-151
58. Lin B, Ginsberg MD, Zhao W, Alonso OF, Belayev L, Busto R (2001) Quantitative analysis of microvascular alterations in traumatic brain injury by endothelial barrier antigen immunohistochemistry. J Neurotrauma 18(4):389-397
59. Park JW, Kim HJ, Song GS, Han HS (2010) Blood-brain barrier experiments with clinical magnetic resonance imaging and an immunohistochemical study. J Korean Neurosurg Soc 47(3):203-209
60. Chekhonin VP, Baklaushev VP, Yusubalieva GM, Pavlov KA, Ukhova OV, Gurina OI (2007) Modeling and immunohistochemical analysis of C6 glioma in vivo. Bull Exp Biol Med 143(4):501-509
61. Andersen C, Jensen FT (1998) Differences in blood-tumour-barrier leakage of human intracranial tumours: quantitative monitoring of vasogenic oedema and its response to glucocorticoid treatment. Acta Neurochir (Wien) 140(9):919-924
62. Greig NH, Jones HB, Cavanagh JB (1983) Blood-brain barrier integrity and host responses in experimental metastatic brain tumours. Clin Exp Metastasis 1(3):229-246
63. Lockman PR, Mittapalli RK, Taskar KS, Rudraraju V, Gril B, Bohn KA, Adkins CE, Roberts A, Thorsheim HR, Gaasch JA, Huang S, Palmieri D, Steeg PS, Smith QR (2010) Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res 16(23):5664-5678
64. Zhang RD, Price JE, Fujimaki T, Bucana CD, Fidler IJ (1992) Differential permeability of the blood-brain barrier in experimental brain metastases produced by human neoplasms implanted into nude mice. Am J Pathol 141(5):1115-1124
65. Nozaki M, Yoshikawa M, Ishitani K, Kobayashi H, Houkin K, Imai K, Ito Y, Muraki T (2010) Cysteinyl leukotriene receptor antagonists inhibit tumor metastasis by inhibiting capillary permeability. Keio J Med 59(1):10-18
66. Zhang M, Olsson Y (1997) Hematogenous metastases of the human brain - characteristics of peritumoral brain changes: a review. J Neurooncol 35(1):81-89
67. Donkin JJ, Nimmo AJ, Cernak I, Blumbergs PC, Vink R (2009) Substance P is associated with the development of brain edema and functional deficits after traumatic brain injury. J Cereb Blood Flow Metab 29(8):1388-1398
68. Alves RV, Campos MM, Santos AR, Calixto JB (1999) Receptor subtypes involved in tachykinin-mediated edema formation. Peptides 20(8):921-927
69. Palma C, Bigioni M, Irrissuto C, Nardelli F, Maggi CA, Manzini S (2000) Anti-tumour activity of tachykinin NK1 receptor antagonists on human glioma U373 MG xenograft. Br J Cancer 82(2):480-487